These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33251996)

  • 1. HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications.
    Kruzikas DT; Malone DC; Pham S; Reinsch TK; Akehurst R
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1548-1557. PubMed ID: 33251996
    [No Abstract]   [Full Text] [Related]  

  • 2. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports.
    Ronquest NA; Paret K; Gould IG; Barnett CL; Mladsi DM
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1601-1612. PubMed ID: 34714108
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of real-world evidence in ICER's scoping process and clinical evidence assessments.
    Jiao B; Veenstra DL; Lee W; Carlson JJ; Devine B
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1590-1595. PubMed ID: 33251999
    [No Abstract]   [Full Text] [Related]  

  • 4. Do Research Groups Align on an Intervention's Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders.
    Sussman M; Yu JC; Menzin J
    Appl Health Econ Health Policy; 2020 Aug; 18(4):477-489. PubMed ID: 31919779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?
    Cohen JT; Silver MC; Ollendorf DA; Neumann PJ
    Value Health; 2019 Dec; 22(12):1396-1401. PubMed ID: 31806196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.
    Chambers JD; Enright DE; Panzer AD; Cohen JT; Ollendorf DA; Neumann PJ
    J Manag Care Spec Pharm; 2023 Mar; 29(3):257-264. PubMed ID: 36840954
    [No Abstract]   [Full Text] [Related]  

  • 7. HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.
    Thokala P; Carlson JJ; Drummond M
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1162-1170. PubMed ID: 32857653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Underestimating the Value of an Intervention: The Case for Including Productivity in Value Assessments and Formulary Design.
    Karmarkar T; Graff JS; Westrich K
    J Manag Care Spec Pharm; 2020 May; 26(5):652-661. PubMed ID: 32347177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports.
    Shafrin J; Dennen S; Pednekar P; Birch K; Bhor M; Kanter J; Neumann P
    J Manag Care Spec Pharm; 2021 May; 27(5):650-659. PubMed ID: 33779245
    [No Abstract]   [Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 12. Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Reports.
    Bloudek LM; Nguyen V; Grueger J; Sullivan SD
    Value Health; 2021 Jun; 24(6):789-794. PubMed ID: 34119076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICER, ISPOR AND QALYs: Tales of Imaginary Worlds.
    Langley PC
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2019; 19(6):1-199. PubMed ID: 30873251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.